Wall Street Analysts Chiming In on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Giving it a 11

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) currently has an A verage Broker Rating of 1.33. This number is based on the 6 sell-side firms polled by Zacks. The ABR rank within the industry stands at 11. Analysts on a consensus basis are expecting that the stock will reach $55.5 within the year.  The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. 

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.

Looking at stock market performance over the last few months, new investors may be worried that they might have missed out on some fantastic opportunities. With so much information and data available, they may not even know where to begin when getting into the stock investing arena. Everybody has to start somewhere, and becoming knowledgeable about the basics may help provide the perfect springboard from which to launch. Starting with the basics may help the investor understand the bigger picture which can then be filtered down into specifics. Because there is no magic formula to achieving success in the stock market, investors may have to explore many different strategies before choosing one to run with.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) closed the last session at $28.91 and sees an average of 885461.13 shares trade hands in each session. The 52-week low of the stock stands at $18.09 while the current level stands at 69.11% of the 52-week High-Low range. Looking further out we can see that the stock has moved 43.85% over the past 12 weeks and 16.3% year to date.

Research analysts are predicting that Aimmune Therapeutics, Inc. (NASDAQ:AIMT) will report earnings of $-1.07 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Most recently Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted quarterly earnings of $-1.01 which compared to the sell-side estimates of -1.01. The stock’s 12-month trailing earnings per share stands at $-3.72. Shares have moved $18.23 over the past month and more recently, $5.1 over the past week heading into the earnings announcement. There are 5 analyst projections that were taken into consideration from respected brokerage firms.

5 analysts rate Aimmune Therapeutics, Inc. a Buy or Strong Buy, which is 83.33% of all the analyst ratings.

Investors may be diving into the latest company earnings reports trying to scope out some quality stocks to add to the portfolio. Nobody knows for sure which way overall market momentum will sway as we near the close of the calendar year. Investors may be getting ready to do a portfolio review to see which stocks are worthy to hold, and which ones have underperformed a may need to be unloaded. Regularly monitoring stock investments may keep the investor ready for any big market changes that may occur.

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.

Leave a Reply

Your email address will not be published. Required fields are marked *

*